Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01852292
Registration number
NCT01852292
Ethics application status
Date submitted
8/05/2013
Date registered
13/05/2013
Titles & IDs
Public title
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Query!
Scientific title
Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Query!
Secondary ID [1]
0
0
2013-000744-26
Query!
Secondary ID [2]
0
0
CBKM120H2201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Head and Neck Squamous Cell Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Head and neck
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Buparlisib
Treatment: Drugs - Buparlisib matching Placebo
Treatment: Drugs - Paclitaxel
Experimental: Buparlisib + weekly Paclitaxel - Patients who were randomized to this arm on a 1:1 randomization, took buparlisib 100 mg daily and paclitaxel 80 mg/m\^2 weekly.
Placebo comparator: Buparlisib matching placebo + Paclitaxel - Patients who were randomized to this arm on a 1:1 randomization, took buparlisib matching placebo 100 mg daily and paclitaxel 80 mg/m\^2 weekly.
Treatment: Drugs: Buparlisib
Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
Treatment: Drugs: Buparlisib matching Placebo
Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
Treatment: Drugs: Paclitaxel
Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS) Per Investigator Assessment
Query!
Assessment method [1]
0
0
PFS was defined as the time from the date of randomization to the date of the event, defined as the first radiologically documented disease progression per RECIST v. 1.1 or death due to any cause. If a patient has not progressed or died at the analysis cut-off date or when the patient receives further anti-neoplastic therapy, PFS was censored on the date of the last adequate tumor assessment before the earlier of the cut-off date or start of the further anti-neoplastic therapy date.
Query!
Timepoint [1]
0
0
4 weeks and thereafter every 6 weeks until disease progression or death up to 3.5 years
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall survival (OS) was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died by the date of analysis cut-off, OS was censored at the date of last contact.
Query!
Timepoint [1]
0
0
4 weeks and thereafter every 6 weeks until disease progression or death up to 3.5 years
Query!
Secondary outcome [2]
0
0
Overall Response Rate (ORR) as Per Local Radiological Assessment
Query!
Assessment method [2]
0
0
ORR: percentage of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1. CR is defined as disappearance of all target lesions and any pathological lymph nodes must have a short axis of \<10 mm and the disappearance of all non-target lesions). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters or the persistence of 1 or more non-target lesions or lymph nodes identified as a site of disease at Baseline with a short axis of =10mm).
Query!
Timepoint [2]
0
0
4 weeks and thereafter every 6 weeks until disease progression or death up to 3.5 years
Query!
Secondary outcome [3]
0
0
Time to Response (TTR) as Per Local Radiological Assessment
Query!
Assessment method [3]
0
0
TTR is the time from date of randomization until first documented response (CR or PR, which has to be confirmed subsequently) according to RECIST v1.1. CR is defined as disappearance of all target lesions and any pathological lymph nodes must have a short axis of \<10 mm and the disappearance of all non-target lesions). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters or the persistence of 1 or more non-target lesions or lymph nodes identified as a site of disease at Baseline with a short axis of =10mm).
Query!
Timepoint [3]
0
0
4 weeks and thereafter every 6 weeks until disease progression or death up to 3.5 years
Query!
Secondary outcome [4]
0
0
Disease Control Rate (DCR) as Per Local Radiological Assessment
Query!
Assessment method [4]
0
0
DCR is the percentage of patients with a best overall response of CR, PR or stable disease (SD), according to RECIST v1.1. CR is defined as disappearance of all target lesions \& any pathological lymph nodes must have a short axis of \<10 mm \& the disappearance of all non-target lesions). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters or the persistence of 1 or more non-target lesions or lymph nodes identified as a site of disease at Baseline with a short axis of =10mm). SD is defined as neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2.
Query!
Timepoint [4]
0
0
4 weeks and thereafter every 6 weeks until disease progression or death up to 3.5 years
Query!
Secondary outcome [5]
0
0
Duration of Response (DoR) as Per Local Investigator
Query!
Assessment method [5]
0
0
DoR is the time from the date of the first documented response (CR or PR, which had to be confirmed subsequently) to the date of the first radiologically documented disease progression or death due to disease according to RECIST v1.1 .
Query!
Timepoint [5]
0
0
4 weeks and thereafter every 6 weeks until disease progression or death up to 3.5 years
Query!
Secondary outcome [6]
0
0
Health-related Quality of Life (HRQoL):Time to 10% Definitive Deterioration in the Global Health Status/Quality of Life Per EORTC-QLQ-C30
Query!
Assessment method [6]
0
0
A summary of EORTC-QLQ-C30 scores by time window. Time to deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen. Definitive Deterioration in global health status and symptoms was defined as a decrease in the subscale score by at least 10% compared to baseline, with no later increase above this threshold observed during the course of the study. If a patient had not had an event prior to analysis cut-off or start of another anticancer therapy, time to deterioration was censored at the date of the last quality of life (QoL) evaluation.
Query!
Timepoint [6]
0
0
Baseline, every 6 weeks starting from cycle 2 day 15 up to 3.5 years
Query!
Secondary outcome [7]
0
0
Health-related Quality of Life (HRQoL):Time to 10% Definitive Deterioration in the Head and Neck Cancer Symptoms Scales for Pain, Speech Problems, Swallowing and Sense Problems Per EORTC-QLQ-HN35
Query!
Assessment method [7]
0
0
A summary of EORTC-QLQ-HN35 scores by time window. Time to deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen. Definitive Deterioration in global health status and symptoms was defined as an increase in the subscale score of at least 10% compared to baseline, with no later decrease above this threshold observed during the course of the study. If a patient had not had an event prior to analysis cut-off or start of another anticancer therapy, time to deterioration was censored at the date of the last quality of life (QoL) evaluation.
Query!
Timepoint [7]
0
0
Baseline, every 6 weeks starting from cycle 2 day 15 up to 3.5 years
Query!
Secondary outcome [8]
0
0
Plasma Concentration-time Profiles of BKM120 Pharmacokinetics (PK) for AUC0-24 and AUClast
Query!
Assessment method [8]
0
0
To Characterize PK of buparlisib given in combination with paclitaxel for AUC0-24 (area under plasma concentration-time curve from time 0 to end of dosing interval of 24 hours) \& AUClast (AUC from time 0 to last measurable concentration sampling time).
Query!
Timepoint [8]
0
0
Time point(s) at which PK samples for Non-Compartmental analysis were collected were 0, 0.5,1,1.5, 2, 3, 4, 6, 9 and 24 hours at Cycle 1, Day 15
Query!
Secondary outcome [9]
0
0
Plasma Concentration-time Profiles of BKM120 Pharmacokinetics (PK) for Cmax
Query!
Assessment method [9]
0
0
To characterize the pharmacokinetics of buparlisib given in combination with paclitaxel for Cmax.
Query!
Timepoint [9]
0
0
Time point(s) at which PK samples for Non-Compartmental analysis were collected were 0, 0.5,1,1.5, 2, 3, 4, 6, 9 and 24 hours at Cycle 1, Day 15
Query!
Secondary outcome [10]
0
0
Plasma Concentration-time Profiles of BKM120 Pharmacokinetics (PK) for Tmax
Query!
Assessment method [10]
0
0
To characterize the pharmacokinetics of buparlisib given in combination with paclitaxel for Tmax.
Query!
Timepoint [10]
0
0
Time point(s) at which PK samples for Non-Compartmental analysis were collected were 0, 0.5,1,1.5, 2, 3, 4, 6, 9 and 24 hours at Cycle 1, Day 15
Query!
Secondary outcome [11]
0
0
Plasma Concentration-time Profiles of BKM120 Pharmacokinetics (PK) for CL/F
Query!
Assessment method [11]
0
0
To characterize the pharmacokinetics of buparlisib given in combination with paclitaxel for CL/F.
Query!
Timepoint [11]
0
0
Time point(s) at which PK samples for Non-Compartmental analysis were collected were 0, 0.5,1,1.5, 2, 3, 4, 6, 9 and 24 hours at Cycle 1, Day 15
Query!
Eligibility
Key inclusion criteria
* Patient has histologically/cytologically-confirmed HNSCC.
* Patient has archival or fresh tumor tissue for the analysis of PI3K-related biomarkers. One tumor block (preferred) or a minimum of 12 unstained slides to be provided. Enrollment in the study is contingent on confirmation of an adequate amount of tumor tissue.
* Patients with recurrent or metastatic disease resistant to platinum-based chemotherapy (defined as progression while on platinum-based chemotherapy given in the recurrent/metastatic setting). Pretreatment with cetuximab is allowed
* Measurable disease as determined by per RECIST criteria v1.1. If the only site of measurable disease is a previously irradiated lesion, documented progression of disease and a 4 week period since radiotherapy completion is required
* Adequate bone marrow function and organ function
* ECOG Performance Status = 1
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patient has received previous treatment with any AKT, mTOR inhibitors or PI3K pathway inhibitors;
* Patient treated with more than one prior chemotherapy regimen for recurrent/metastatic disease
* Patient has symptomatic CNS metastases. Patients with asymptomatic CNS metastases may participate in this trial. The patient must have completed any prior local treatment for CNS metastases = 28 days prior to the start of study treatment (including radiotherapy and/or surgery) and must have stable low dose of corticosteroid therapy;
* Patient has not recovered to = grade 1 (except alopecia) from related side effects of any prior antineoplastic therapy
* Patient has any of the following cardiac abnormalities:symptomatic congestive heart failure, history of documented congestive heart failure (New York Heart Association functional classification III-IV), documented cardiomyopathy, Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO); myocardial infarction = 6 months prior to enrolment, unstable angina pectoris, serious uncontrolled cardiac arrhythmia, symptomatic pericarditis, QTcF > 480 msec on the screening ECG (using the QTcF formula);
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/03/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
157
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - St Leonards
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Massachusetts
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Missouri
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New York
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
North Carolina
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Ohio
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Pennsylvania
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Ontario
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Quebec
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Saint Herblain cedex
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Berlin
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Essen
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Hannover
Query!
Country [14]
0
0
Hungary
Query!
State/province [14]
0
0
Budapest
Query!
Country [15]
0
0
Hungary
Query!
State/province [15]
0
0
Nyiregyhaza
Query!
Country [16]
0
0
India
Query!
State/province [16]
0
0
Maharashtra
Query!
Country [17]
0
0
India
Query!
State/province [17]
0
0
New Delhi
Query!
Country [18]
0
0
India
Query!
State/province [18]
0
0
Rajasthan
Query!
Country [19]
0
0
India
Query!
State/province [19]
0
0
West Bengal
Query!
Country [20]
0
0
India
Query!
State/province [20]
0
0
Kerala
Query!
Country [21]
0
0
India
Query!
State/province [21]
0
0
Mumbai
Query!
Country [22]
0
0
Ireland
Query!
State/province [22]
0
0
Dublin 4
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
FI
Query!
Country [24]
0
0
Italy
Query!
State/province [24]
0
0
MI
Query!
Country [25]
0
0
Italy
Query!
State/province [25]
0
0
PA
Query!
Country [26]
0
0
Italy
Query!
State/province [26]
0
0
RM
Query!
Country [27]
0
0
Italy
Query!
State/province [27]
0
0
SA
Query!
Country [28]
0
0
Italy
Query!
State/province [28]
0
0
TO
Query!
Country [29]
0
0
Italy
Query!
State/province [29]
0
0
VE
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Chiba
Query!
Country [31]
0
0
Japan
Query!
State/province [31]
0
0
Tokyo
Query!
Country [32]
0
0
Korea, Republic of
Query!
State/province [32]
0
0
Korea
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Seocho-gu
Query!
Country [34]
0
0
Poland
Query!
State/province [34]
0
0
Warszawa
Query!
Country [35]
0
0
Russian Federation
Query!
State/province [35]
0
0
Russia
Query!
Country [36]
0
0
Russian Federation
Query!
State/province [36]
0
0
Nizhniy Novgorod
Query!
Country [37]
0
0
Russian Federation
Query!
State/province [37]
0
0
St. Petersburg
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Catalunya
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Madrid
Query!
Country [40]
0
0
Switzerland
Query!
State/province [40]
0
0
Basel
Query!
Country [41]
0
0
Switzerland
Query!
State/province [41]
0
0
Genève
Query!
Country [42]
0
0
Taiwan
Query!
State/province [42]
0
0
Taiwan ROC
Query!
Country [43]
0
0
Taiwan
Query!
State/province [43]
0
0
Kaohsiung City
Query!
Country [44]
0
0
Taiwan
Query!
State/province [44]
0
0
Taichung City
Query!
Country [45]
0
0
Thailand
Query!
State/province [45]
0
0
Hat Yai
Query!
Country [46]
0
0
Thailand
Query!
State/province [46]
0
0
Bangkok
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
Scotland
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
London
Query!
Country [49]
0
0
United Kingdom
Query!
State/province [49]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Phase II Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic Head and Neck cancer previously pre-treated with a platinum therapy.The primary endpoint was PFS and the key secondary endpoint was Overall Survival.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01852292
Query!
Trial related presentations / publications
Soulieres D, Faivre S, Mesia R, Remenar E, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamas L, Kim SB, Erfan J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. Epub 2017 Jan 26.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/92/NCT01852292/SAP_000.pdf
Study protocol
https://cdn.clinicaltrials.gov/large-docs/92/NCT01852292/Prot_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01852292